Related Experiment Videos
Production of clinical-grade recombinant adeno-associated virus vectors
Richard O Snyder1, Terence R Flotte
1Powell Gene Therapy Center, University of Florida Genetics Institute, Department of Pediatrics, 1600 SW Archer Road, Gainesville, FL 32610-0266, USA.
Current Opinion in Biotechnology
|December 3, 2002
Abstract:
Recombinant adeno-associated viral (rAAV) vectors are being evaluated in animal models and humans. Pre-clinical data demonstrating vector safety, efficiency and efficacy have been used to initiate human clinical trials. The clinical manufacture of rAAV vectors has supported phase I and phase II trials, showing that adeno-associated virus serotype 2 vectors are safe when administered to humans.